AKT1 and chronic myelogenous leukemia, BCR-ABL1 positive: Furthermore a Rac-specific small molecule inhibitor (NSC23766) was able to reduce the leukemic burden in vivo in NOD/SCID mice transplanted with chronic-phase CML CD34+ cells [22].